G PrayGod1, N Range2, D Faurholt-Jepsen3, K Jeremiah1, M Faurholt-Jepsen3, M G Aabye4, P Magnussen5, J Changalucha1, A B Andersen6, J C K Wells7, H Friis3. 1. Mwanza Intervention Trials Unit, Mwanza Research Centre, National Institute for Medical Research, Mwanza, Tanzania. 2. Muhimbili Research Centre, National Institute for Medical Research, Dar es Salaam, Tanzania. 3. Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark. 4. Clinical Research Centre, University of Copenhagen, Hvidovre Hospital, Hvidovre, Denmark. 5. Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 6. Department of Infectious Diseases, Odense University Hospital, Odense, Denmark. 7. Childhood Nutrition Research Centre, UCL-Institute of Child Health, London, UK.
Abstract
BACKGROUND/ OBJECTIVES: Gains in fat mass and lean mass during tuberculosis (TB) treatment may determine functional recovery and survival; yet, data are scarce. We aimed to assess predictors of fat and fat-free mass during 2 months of intensive TB treatment in a cohort in Mwanza, Tanzania. SUBJECTS/ METHODS: Fat and fat-free mass were determined at the start of TB treatment and repeated after 2 months using the deuterium dilution technique. Gains in fat and fat-free mass were determined and predictors assessed using regression analysis. RESULTS: Data for 116 patients were available at baseline and during follow-up. Of these, 38.8% were females, mean age was 37.3 (s.d. 13.5) years, 69% (81) had sputum-positive TB, 45.7% (53) were HIV infected and 25% (29) were current smokers. The mean weight gain was 3.3 kg (95% confidence interval: 2.7; 3.8), and it did not differ by sex. However, compared with females, males had 1.0 (0.4; 1.6) kg/m(2) lower fat mass but 0.7 (0.2; 1.3) kg/m(2) higher fat-free mass gain. Current smoking was associated with higher fat mass (0.7 kg/m(2), 0.04; 1.4) but lower fat-free mass (-0.5 kg/m(2), -1.2; 0.07) gain. Among HIV-infected patients, antiretroviral therapy (ART) led to a lower fat gain (-1.2 kg/m(2), -2.2; -0.2) but to a higher fat-free mass among sputum-negative (2.9 kg/m(2), 0.8; 5.1) but not sputum-positive patients. CONCLUSIONS: During intensive phase of TB treatment, sex, smoking and ART were predictors of body composition. Larger studies are needed to further understand predictors of body composition during recovery, to help design interventions to improve treatment outcomes.
BACKGROUND/ OBJECTIVES: Gains in fat mass and lean mass during tuberculosis (TB) treatment may determine functional recovery and survival; yet, data are scarce. We aimed to assess predictors of fat and fat-free mass during 2 months of intensive TB treatment in a cohort in Mwanza, Tanzania. SUBJECTS/ METHODS:Fat and fat-free mass were determined at the start of TB treatment and repeated after 2 months using the deuterium dilution technique. Gains in fat and fat-free mass were determined and predictors assessed using regression analysis. RESULTS: Data for 116 patients were available at baseline and during follow-up. Of these, 38.8% were females, mean age was 37.3 (s.d. 13.5) years, 69% (81) had sputum-positive TB, 45.7% (53) were HIV infected and 25% (29) were current smokers. The mean weight gain was 3.3 kg (95% confidence interval: 2.7; 3.8), and it did not differ by sex. However, compared with females, males had 1.0 (0.4; 1.6) kg/m(2) lower fat mass but 0.7 (0.2; 1.3) kg/m(2) higher fat-free mass gain. Current smoking was associated with higher fat mass (0.7 kg/m(2), 0.04; 1.4) but lower fat-free mass (-0.5 kg/m(2), -1.2; 0.07) gain. Among HIV-infectedpatients, antiretroviral therapy (ART) led to a lower fat gain (-1.2 kg/m(2), -2.2; -0.2) but to a higher fat-free mass among sputum-negative (2.9 kg/m(2), 0.8; 5.1) but not sputum-positive patients. CONCLUSIONS: During intensive phase of TB treatment, sex, smoking and ART were predictors of body composition. Larger studies are needed to further understand predictors of body composition during recovery, to help design interventions to improve treatment outcomes.
Authors: George PrayGod; Nyagosya Range; Daniel Faurholt-Jepsen; Kidola Jeremiah; Maria Faurholt-Jepsen; Martine G Aabye; Lotte Jensen; Andreas V Jensen; Harleen M S Grewal; Pascal Magnussen; John Changalucha; Aase Bengaard Andersen; Henrik Friis Journal: Trans R Soc Trop Med Hyg Date: 2011-01-15 Impact factor: 2.184
Authors: Nyagosya Range; John Changalucha; Henrik Krarup; Pascal Magnussen; Ase B Andersen; Henrik Friis Journal: Br J Nutr Date: 2006-04 Impact factor: 3.718
Authors: Ezekiel Mupere; Sarah Zalwango; Allan Chiunda; Alphonse Okwera; Roy Mugerwa; Christopher Whalen Journal: Ann Epidemiol Date: 2010-03 Impact factor: 3.797
Authors: Lauren S Peetluk; Peter F Rebeiro; Marcelo Cordeiro-Santos; Afranio Kritski; Bruno B Andrade; Betina Durovni; Solange Calvacante; María B Arriaga; Megan M Turner; Marina C Figueiredo; Valeria C Rolla; Timothy R Sterling Journal: J Infect Dis Date: 2020-04-07 Impact factor: 5.226
Authors: Suzanne Filteau; George PrayGod; Andrea M Rehman; Robert Peck; Kidola Jeremiah; Rikke Krogh-Madsen; Daniel Faurholt-Jepsen Journal: Am J Clin Nutr Date: 2021-06-01 Impact factor: 7.045
Authors: George PrayGod; Suzanne Filteau; Nyagosya Range; Kaushik Ramaiya; Kidola Jeremiah; Andrea M Rehman; Rikke Krogh-Madsen; Henrik Friis; Daniel Faurholt-Jepsen Journal: PLoS One Date: 2022-01-25 Impact factor: 3.752